Clinical Trials
8 trialsNCT05918055 2025-12-02
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05148234 2025-09-30
BMS-986253 in Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00701298 2014-02-24
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00049582 2013-09-30
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00748527 2013-07-10
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00042796 2013-01-23
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00089089 2013-01-07
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated